Literature DB >> 24507092

Rifampicin for multiple system atrophy.

Gregor K Wenning1, Florian Krismer2, Werner Poewe2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24507092      PMCID： PMC6200132          DOI： 10.1016/S1474-4422(14)70022-5

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  15 in total

Review 1.  Multiple system atrophy--the nature of the beast.

Authors:  N Quinn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

2.  Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy.

Authors:  Kiren Ubhi; Edward Rockenstein; Michael Mante; Christina Patrick; Anthony Adame; Monica Thukral; Clifford Shults; Eliezer Masliah
Journal:  Neuroreport       Date:  2008-08-27       Impact factor: 1.837

3.  α-synuclein imaging: a critical need for Parkinson's disease research.

Authors:  Jamie L Eberling; Kuldip D Dave; Mark A Frasier
Journal:  J Parkinsons Dis       Date:  2013       Impact factor: 5.568

4.  Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.

Authors:  Rachelle S Doody; Ronald G Thomas; Martin Farlow; Takeshi Iwatsubo; Bruno Vellas; Steven Joffe; Karl Kieburtz; Rema Raman; Xiaoying Sun; Paul S Aisen; Eric Siemers; Hong Liu-Seifert; Richard Mohs
Journal:  N Engl J Med       Date:  2014-01-23       Impact factor: 91.245

5.  Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy.

Authors:  J G Graham; D R Oppenheimer
Journal:  J Neurol Neurosurg Psychiatry       Date:  1969-02       Impact factor: 10.154

6.  Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG).

Authors:  Felix Geser; Gregor K Wenning; Klaus Seppi; Michaela Stampfer-Kountchev; Christoph Scherfler; Martin Sawires; Carolin Frick; Jean-Pierre Ndayisaba; Hanno Ulmer; Maria T Pellecchia; Paolo Barone; Hee T Kim; Juzar Hooker; Niall P Quinn; Adriana Cardozo; Eduardo Tolosa; Michael Abele; Thomas Klockgether; Karen Østergaard; Erik Dupont; Nicole Schimke; Karla M Eggert; Wolfgang Oertel; Ruth Djaldetti; Werner Poewe
Journal:  Mov Disord       Date:  2006-02       Impact factor: 10.338

7.  Progression of putaminal degeneration in multiple system atrophy: a serial diffusion MR study.

Authors:  Klaus Seppi; Michael F H Schocke; Katherina J Mair; Regina Esterhammer; Christoph Scherfler; Felix Geser; Christian Kremser; Sylvia Boesch; Werner Jaschke; Werner Poewe; Gregor K Wenning
Journal:  Neuroimage       Date:  2006-01-27       Impact factor: 6.556

8.  Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome).

Authors:  M I Papp; J E Kahn; P L Lantos
Journal:  J Neurol Sci       Date:  1989-12       Impact factor: 3.181

9.  A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease.

Authors: 
Journal:  JAMA Neurol       Date:  2013-01       Impact factor: 18.302

10.  The natural history of multiple system atrophy: a prospective European cohort study.

Authors:  Gregor K Wenning; Felix Geser; Florian Krismer; Klaus Seppi; Susanne Duerr; Sylvia Boesch; Martin Köllensperger; Georg Goebel; Karl P Pfeiffer; Paolo Barone; Maria Teresa Pellecchia; Niall P Quinn; Vasiliki Koukouni; Clare J Fowler; Anette Schrag; Christopher J Mathias; Nir Giladi; Tanya Gurevich; Erik Dupont; Karen Ostergaard; Christer F Nilsson; Håkan Widner; Wolfgang Oertel; Karla Maria Eggert; Alberto Albanese; Francesca del Sorbo; Eduardo Tolosa; Adriana Cardozo; Günther Deuschl; Helge Hellriegel; Thomas Klockgether; Richard Dodel; Cristina Sampaio; Miguel Coelho; Ruth Djaldetti; Eldad Melamed; Thomas Gasser; Christoph Kamm; Giuseppe Meco; Carlo Colosimo; Olivier Rascol; Wassilios G Meissner; François Tison; Werner Poewe
Journal:  Lancet Neurol       Date:  2013-02-05       Impact factor: 44.182
View more
  2 in total

Review 1.  Current Management and Emerging Therapies in Multiple System Atrophy.

Authors:  Matthew R Burns; Nikolaus R McFarland
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 6.088

Review 2.  Towards translational therapies for multiple system atrophy.

Authors:  Daniela Kuzdas-Wood; Nadia Stefanova; Kurt A Jellinger; Klaus Seppi; Michael G Schlossmacher; Werner Poewe; Gregor K Wenning
Journal:  Prog Neurobiol       Date:  2014-03-02       Impact factor: 11.685
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.